The patient impact of 10 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies

被引：0
|
作者：
Weber, Martin [1 ,2 ,3 ]
Kappos, Ludwig [4 ]
Hauser, Stephen [5 ]
Nicholas, Jacqueline [6 ]
Schneble, Hans-Martin [7 ]
Wang, Qing [7 ]
Giovannoni, Gavin [8 ]
Filippi, Massimo [9 ,10 ]
机构：
[1] Inst Neuropathol, Dept Neurol, Gottingen, Germany
[2] Univ Med Ctr, Gottingen, Germany
[3] Fraunhofer Inst Translat Med & Pharmacol ITMP, Gottingen, Germany
[4] Univ Basel, Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland
[5] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA USA
[6] OhioHlth Multiple Sclerosis Clin, Columbus, OH USA
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Queen Mary Univ London, London, England
[9] IRCCS San Raffaele Sci Inst, Neurol Unit, Neurophysiol Serv, Neurorehabil Unit,Neuroimaging Res Unit,Div Neuro, Milan, Italy
[10] Univ Vita Salute San Raffaele, Milan, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P302/406
引用
收藏
页码：350 / 351
页数：2
相关论文
共 50 条
  • [31] Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS Nine-Year Data From the OPERA Studies Open-Label Extension
    Cerqueira, Joao J.
    Berthele, Achim
    Cree, Bruce A. C.
    Filippi, Massimo
    Pardo, Gabriel
    Pearson, Owen R.
    Traboulsee, Anthony
    Ziemssen, Tjalf
    Vollmer, Timothy
    Bernasconi, Corrado
    Mandel, Corey R.
    Kulyk, Inessa
    Chognot, Cathy
    Raposo, Catarina
    Schneble, Hans-Martin
    Thanei, Gian-Andrea
    Incera, Elodie
    Havrdova, Eva K.
    NEUROLOGY, 2025, 104 (04)
  • [32] The long-term impact of early treatment of multiple sclerosis on the risk of disability pension
    Erik Landfeldt
    Anna Castelo-Branco
    Axel Svedbom
    Emil Löfroth
    Andrius Kavaliunas
    Jan Hillert
    Journal of Neurology, 2018, 265 : 701 - 707
  • [33] Quetiapine in the maintenance treatment of bipolar I disorder: Combined data from two long-term phase III studies
    Brecher, Martin
    Liu, Sherry
    Paulsson, Bjorn
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 180S - 181S
  • [34] Quetiapine in the maintenance treatment of bipolar I disorder: Combined data from two long-term, phase III studies
    Vieta, E.
    Brecher, M.
    Suppes, T.
    Liu, S.
    Paulsson, B.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 185 - 186
  • [35] The long-term impact of early treatment of multiple sclerosis on the risk of disability pension
    Landfeldt, Erik
    Castelo-Branco, Anna
    Svedbom, Axel
    Lofroth, Emil
    Kavaliunas, Andrius
    Hillert, Jan
    JOURNAL OF NEUROLOGY, 2018, 265 (03) : 701 - 707
  • [36] Quetiapine in the maintenance treatment of bipolar I disorder: Combined data from two long-term phase III studies
    Brecher, M.
    Anderssen, H.
    Paulsson, B.
    BIPOLAR DISORDERS, 2008, 10 : 40 - 40
  • [37] Quetiapine in the maintenance treatment of bipolar I disorder: Combined data from two long-term phase III studies
    Brecher, M.
    Anderssen, H.
    Paulsson, B.
    EUROPEAN PSYCHIATRY, 2008, 23 : S226 - S226
  • [38] How to estimate long-term treatment effects in multiple sclerosis registry studies
    Allignol, Arthur
    Spelman, Tim
    Freilich, Jonatan
    Sabido, Meritxell
    Gillett, Alan
    Hillert, Jan
    Boutmy, Emmanuelle
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 63 - 64
  • [39] Lessons learned from long-term multiple sclerosis treatment trials
    Marriott, James J.
    O'Connor, Paul W.
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (09) : 1028 - 1030
  • [40] Long-Term Reduction in 48-Week Confirmed Disability Progression After 5 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis [Encore]
    Parratt, J.
    Hauser, S. L.
    Kappos, L.
    Montalban, X.
    Bar-Or, A.
    Giovannoni, G.
    Model, F.
    Prajapati, K.
    Manfrini, M.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP66 - NP67
12345